Zobrazeno 1 - 10
of 791
pro vyhledávání: '"Sarilumab"'
Autor:
Alan Kivitz, Jacques Eric Gottenberg, Martin Bergman, Chunfu Qiu, Hubert van Hoogstraten, Ron de Nijs, Louis Bessette
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 6, Pp 1533-1550 (2024)
Abstract Introduction The 1-year PROspective sarilumab (preFILled syringe/pen) multinational, obsErvational (PROFILE) study evaluated the real-world effectiveness and safety of sarilumab in patients with moderate-to-severe rheumatoid arthritis (RA).
Externí odkaz:
https://doaj.org/article/f98da2876c6e42148dfe1f0f8228c479
Autor:
Yousef Jafari Abarghan, Mohammad Heiat, Abolfazl Jahangiri, Mohammad Hossein Peypar, Mahdi Abdorrashidi, Amirmohammad Tohidinia, Mahmood Salesi, Shahrzad Tajik, Farnaz Farzaneh Dehkordi, Hamid Sedighian
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 54, Iss , Pp 101483- (2024)
Background: Monoclonal antibodies (mAbs) are currently under investigation as a potential therapeutic option for COVID-19. Clinical trials are examining their efficacy in lowering mortality rates and the requirement for mechanical ventilation (MV). I
Externí odkaz:
https://doaj.org/article/2bf9634225bf47f0b27fa342506b356b
Publikováno v:
Journal of Plastic and Reconstructive Surgery, Vol 3, Iss 2, Pp 83-88 (2024)
A 77-year-old woman who had been taking iguratimod and sarilumab for rheumatoid arthritis for 3 months had gas gangrene. After hospitalization, she underwent two debridement surgeries, one drainage procedure, and a free latissimus dorsi musculocutane
Externí odkaz:
https://doaj.org/article/7d13ed87597c40498ae85694985a2c4e
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 6, Pp 658-666 (2024)
Interleukin (IL) 6 is one of the key cytokines whose role in the inflammation development in rheumatoid arthritis (RA), is well proven. The pleiotropic effects of the cytokine and biologic agents that inhibit its action have been studied much worse.
Externí odkaz:
https://doaj.org/article/20fae97266bd4434bed27e5c42d753fc
Autor:
V. T. Ivashkin, R. V. Maslennikov, E. V. Vasilieva, M. L. Chipurik, P. A. Semikova, V. V. Semenets, T. A. Russkova
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 33, Iss 5, Pp 54-64 (2023)
Objective. Cytokine release syndrome (CRS) is a dangerous complication of the new coronavirus infection (COVID-19). The study aimed to compare sarilumab (SAR group) with tocilizumab (TOC group) and patients without anticytokine treatment (CON group)
Externí odkaz:
https://doaj.org/article/1596e4d0681a4639955eb64d26e77009
Autor:
Luis Sainz, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar Díaz-Torné, Ana Milena Millán, Hye Sang Park, Adriana Lasa, Hector Corominas
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-10 (2023)
Abstract Background Sarilumab, an IL-6 receptor antagonist, is a first-line biologic disease-modifying anti-rheumatic drug for rheumatoid arthritis. The identification of genetic biomarkers as predictors of response to sarilumab could allow for a per
Externí odkaz:
https://doaj.org/article/0444fe7ddf56436ab6f8401650ec4da3
Autor:
Wolfgang A. Schmidt, Bhaskar Dasgupta, Jennifer Sloane, Angeliki Giannelou, Yuqing Xu, Sebastian H. Unizony, Sarah L. Mackie, Miguel A. Gonzalez-Gay, Robert Spiera, Kenneth J. Warrington, Peter M. Villiger, Michael C. Nivens, Bolanle Akinlade, Yong Lin, Frank Buttgereit, John H. Stone
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-16 (2023)
Abstract Background Giant cell arteritis (GCA) is primarily treated with glucocorticoids (GCs), which have substantial toxicity. Tocilizumab, an interleukin-6-receptor inhibitor (IL-6Ri), showed beneficial effects in GCA, leading to its approval. Thi
Externí odkaz:
https://doaj.org/article/4519641ec60d4627b6d5c6d36c1bb6ac
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Anvitha Madhavaram, Bashar Kahaleh
Publikováno v:
Translation, Vol 11, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/68a3cb11fc514a5baba97f9a98f01136
Autor:
Maaike C. Swets, Rob J. Moss, Flip Kor, Doranne Hilarius, Dirk Jan A.R. Moes, Willemijn EM Berkhout, Leon M. van den Toorn, Niels C. Gritters van den Oever, Renee de Valk, Frits R. Rosendaal, Nicole Hunfeld, Geert H. Groeneveld, Mark G.J. de Boer
Publikováno v:
International Journal of Infectious Diseases, Vol 129, Iss , Pp 57-62 (2023)
Objectives: Interleukin (IL)-6 inhibitors are administered to treat patients hospitalized with COVID-19. In 2021, due to shortages, different dosing regimens of tocilizumab, and a switch to sarilumab, were consecutively implemented. Using real-world
Externí odkaz:
https://doaj.org/article/272003f490b749cda7c4f1c7f333c48d